Navidea Biopharmaceuticals, Inc. Disclosure

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a client of PCG Advisory, Inc. NAVB has an agreement in place to pay PCG a monthly cash fee of $5,000, a one-time stock fee of 20,000 shares of common stock, restricted under Rule 144, plus an additional one-time stock fee issuance on January 5, 2020 of $30,000 in shares of common stock, restricted under Rule 144, calculated using the closing price of the stock on December 31, 2019, less the initial 20,000 shares, for PCG investor awareness and investor relations advisory services.

Investor awareness and investor relations services and programs are designed to help small-cap companies communicate their investment characteristics. PCG investor awareness and advisory services include multimedia marketing and other awareness services.